High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.

EBioMedicine · 2016 · PMC5161445 · PMID 27916548

Europe PMC DOI

hedged sentence

0.1820

closest p · 3.6× alpha

0.1820

boldest claim

The sentences

showed a trendP = 0.182not close (p > 0.1)

Firstly, compared to CPT1A low , DNMT3A and DNMT3B showed significantly higher expression in CPT1A high group ( P = 0.001 and P < 0.001, respectively), and DNMT1 also showed a trend of higher expression ( P = 0.182) ( Fig. 5 A).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.